Table 5 Kawasaki features and associated symptoms of Kawasaki disease shock syndrome, and Septic shock group
From: Clinical aspects for differential diagnosis of Kawasaki disease shock syndrome: a case control study
KDSS(n=13) | SS (n=29) | P value | |
|---|---|---|---|
Kawasaki features | |||
Conjunctival injection | 92.3% (12/13) | 10.3% (3/29) | 0.000 |
Oropharyngeal changes | 84.6% (11/13) | 17.2% (5/29) | 0.000 |
Polymorphous rash | 76.9% (10/13) | 69.0% 1 (20/29) | 0.722 |
Cervical lymphadenopathy | 69.2% (9/13) | 3.4%(1/29) | 0.000 |
Extremity changes | 92.3% (12/13) | 34.5% (10/29) | 0.001 |
Associated symptoms | |||
Gastrointestinal symptoms | 84.6% (11/13) | 82.8% (24/29) | 1.000 |
Respiratory symptoms | 76.9% (10/13) | 41.4% (12/29) | 0.033 |
Neurologic symptoms | 23.1% (3/13) | 51.7% (15/29) | 0.083 |
Systemic pain | 53.8% (7/13) | 37.9% (11/29) | 0.335 |
Pleural effusion | 76.9% (10/13) | 41.4% (12/29) | 0.033 |
Organ damage | 92.3% (12/13) | 82.8% (24/29) | 0.647 |